

## **Jennifer Molloy**

506 W. Howe St., Tempe, AZ 85281  
(503) 830-1543

### **EDUCATION**

**CCL, Biotechnology**, May 2019

Mesa Community College

GPA: 3.75

**B.S., Biological Sciences**, May 2016

Arizona State University

GPA: 3.24

### **RESEARCH EXPERIENCE**

**Virginia D. Piper Center for Personalized Diagnostics at ASU BioDesign Institute**, April 2024 - present  
*Research Specialist*

- Perform HD NAPPA assays to screen human samples for potential biomarkers for different cancers
- Analyze and compile data from NAPPA arrays that can be used for statistical analysis

PI: Dr. Ji Qiu, Research Professor

**Ivy Brain Tumor Center at the Barrow Neurological Institute**, May 2020 – April 2024

*Research Technician II, General Supervisor of ANP of CAP/CLIA Lab*

- In a CAP/CLIA certified clinical lab, screen brain tumor tissues from >200 patients via next-generation sequencing and immunohistochemistry for personalized recommendation across 8 clinical trials
- Perform analysis of biomarkers in archival and post-treatment operative tissue to assess pharmacodynamic response
- Perform histological embedding and sectioning of clinical and non-clinical tissue samples
- Perform immunohistochemistry assays on 6 pre-clinical research projects pertaining to drug response and effects on mechanisms of disease

PI: Dr. An-Chi Tien, Research Assistant Professor of Pharmacodynamics

**University of Arizona College of Medicine-Phoenix**, February 2019 – May 2019

*Research Intern*

- Contributed to research on the role of nuclear pore proteins Nup98, Nup62 and Nup153 in transcriptional memory and the antiviral response to poliovirus in HeLa cells, resulting in the identification of a novel intermediate cleavage product
- Learned and performed western blot and viral plaque assays
- Presented a poster and rapid-fire talk at the 2019 Arizona Symposium of Virology, Immunology, Microbiomes, and Infectious Disease

PI: Dr. Kurt Gustin, Associate Professor, Basic Medical Sciences

### **RESEARCH INTERESTS**

Neuro-oncology, mechanisms of disease resistance, tumor biology and microenvironment, epigenetics, biomarkers, and cell biology.

### **POSTERS & PRESENTATIONS**

Mehta, S., Tien, A.-C., Patel, S., Margaryan T., **Molloy, J.**, Knight, W., Hon, R., Elliott M., Stavnichuk, M., Opachich, Z., Chang, Y.-W., Montgomery, C. Himes, S., Hopkins, B., Tovmasyan, A., Sanai, N. (2022). Tumor Pharmacokinetics, Pharmacodynamics and Radiation Sensitization in Patient-Derived Models of Glioblastoma Treated with the WEE1 inhibitor, Zn-c3. Abstract presented at 2022 Society of Neuro-Oncology Annual Meeting.

Sanai, N., Margaryan, T., **Molloy, J.**, Knight, W., Harmon, J., Hong, A., Wanebo, J. Kennedy, B., Garcia, M., Barani, I., Yoo, W., Tien, A.-C., Tovmasyan, A., Mehta, S. (2022). A Phase 0 'Trigger' Trial of Niraparib in Newly-Diagnosed Glioblastoma Patients. Abstract presented at 2022 Society of Neuro-Oncology Annual Meeting.

Sanai, N., Chang, Y.-W., Jiang, J., **Molloy, J.**, Pennington-Krygier, C., Harmon, J., Hong, A., Wanebo, J., Kennedy, W., Garcia, M., Barani, I., Yoo, W., Tovmasyan, A., Tien, A.-C., Li, J., Mehta, S. (2022). A Phase 0 'Trigger' Trial of Pamiparib in Newly Diagnosed and Recurrent Glioblastoma Patients. Abstract presented at 2022 Society of Neuro-Oncology Annual Meeting.

Huttenlocher, D., **Molloy, J.**, Patel, S., Stavnichuk, M., Opachich, Z., Elena, L., White, C., Mehta, S., Tien, A.-C. (2022). Temporal characterization of pharmacodynamics changes with combination treatment of valproic acid and irradiation in intracranial glioma patient-derived xenograft mouse models. Summer intern presentation, Department of translational science, Barrow Neurological Institute.

**Molloy, J.**, Le, S., Sullivan, B.E., Gustin, K. E. (2019). Epigenetic transcriptional memory attenuates virus replication. Poster and Presentation at Arizona Symposium on Virology, Immunology, Microbiomes, and Infectious Disease.

#### **PUBLISHED ABSTRACTS**

Chang, Y.W., DeSantis, A., Pennington-Krygier, C., **Molloy, J.**, Mehta, S.; Sanai, N., & Tien, A.C. (2021). Feasibility of Single-Pass Stereotactic Needle Biopsy in Recurrent Glioblastoma Patients to Support CLIA-Certified Tumor Pharmacodynamics for a Phase 0/2 Clinical Trial. *Neuro-Oncology*, 23(Issue Supplement\_6), vi63. <https://doi.org/10.1093/neuonc/noab196.245>,  
Mehta, S., Tovmasyan, A., Tien, A.C., Holter, M., Hopkins, B., Margaryan, T., Chang, Y.W., Himes, S., Elliot, M., Melendez, E.L., Pennington-Krygier, C., White, C., **Molloy, J.**, Liu, M., Knight, W., & Sanai, N. (2021). Tumor Pharmacokinetics, Pharmacodynamics and Radiation Sensitization in Patient-Derived Xenograft Models of Glioblastoma Treated with the Aurora Kinase A Inhibitor LY3295668. *Neuro-Oncology*, 23(Issue Supplement\_6), vi165. <https://doi.org/10.1093/neuonc/noab196.648>

Sanai, N., Margaryan, T., **Molloy, J.**, DeSantis, A., Harmon, J., Hong, A., ... Mehta, S. (2023). A phase 0 pharmacokinetic trigger trial of ifigritinib in patients with recurrent high-grade glioma. *Journal of Clinical Oncology*, 41(Number 16\_suppl), 2051–2051. [https://doi.org/10.1200/JCO.2023.41.16\\_suppl.2051](https://doi.org/10.1200/JCO.2023.41.16_suppl.2051)

#### **TECHNICAL SKILLS**

**Computational:** Aperio ImageScope, Microsoft Office suite, Google suite, Smartsheet, redCap

**Laboratory:** Next-generation sequencing (Qiagen, Illumina), pyrosequencing (Qiagen), immunohistochemistry (Leica), gel electrophoresis, western blot, ELISA assays, cell culture, viral plaque assays, histological sectioning, DNA/RNA extraction

**Other:** CITI certified, experience working in a CAP/CLIA accredited lab, CAP inspector trained